Impact of new treatment options for hepatitis C virus infection in liver transplantation

Table 1 Expected benefits of new treatments for hepatitis C virus infection

Target population	Main objectives	Outcome
General population with chronic HCV infection	Achieve excellent SVR rates for all genotypes, reduce side effects, shorten treatment duration, simplify regimen schedules	Reduced ESLD incidence and indication for LT
Patients on LT waiting list	Achieve pre-transplant undetectable HCV-RNA; improve MELD scores	Reduced post-LT HCV recurrence; improved clinical conditions
Recipients of LT with HCV recurrence	Increase SVR rates, reduce side effects and dropouts, decrease drug-drug interactions, simplify regimen schedules	Increased patients and grafts survival
HIV/HCV-coinfected patients and coinfected LT recipients	Increase SVR rates, reduce side effects and dropouts, decrease drug-drug interactions, simplify regimen schedules	Increased patients and grafts survival

HCV: Hepatitis C virus; SVR: Sustained virological response; ESLD: End stage liver disease; LT: Liver transplant; MELD: Model for end-stage liver disease; HIV: Human immunodeficiency virus.